Hatteras Discovery

Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

Wildflower Health, Inc. is a San Francisco-based company that provides smartphone-based health programs designed to help healthcare payers connect with families across the United States. Its flagship offering, Due Date Plus, is a maternity program that engages women in early pregnancy and facilitates connections with healthcare providers or care managers. Additionally, Wildflower Health offers GROW, a family health program that addresses the needs of mothers and pediatric health. The company delivers tailored health milestones for families based on age and gender, along with features such as client resource integrations, on-device messaging, appointment reminders, health risk assessments, and clinical program referrals. Founded in 2012, Wildflower Health aims to enhance user engagement and improve healthcare experiences through innovative technology and design.

Huma.AI, Inc. is a technology company based in Palo Alto, California, that focuses on knowledge automation for the pharmaceutical and healthcare industries. Incorporated in 2016, Huma.AI addresses inefficiencies caused by complex and disconnected systems that hinder data accessibility and insights. The company's platform connects disparate data silos through natural language processing, enabling users to easily access information and gain actionable insights without requiring specialized technical knowledge. By simplifying interactions with data, Huma.AI aims to enhance decision-making and operational efficiency in a sector characterized by an overwhelming volume of information.

AN2 Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of novel medicines targeting infectious diseases. The company focuses on developing a clinical-stage antibacterial compound. It has a strategic partnership with Brii Biosciences. The company was incorporated in 2017 and is based in Menlo Park, California.

Tune Therapeutics is focused on developing innovative cell and gene therapies that utilize epigenetic programming to address serious diseases. By harnessing the potential of the epigenome, the company aims to create new therapeutic pathways that modify biological functions without changing the underlying DNA sequence. This approach seeks to provide effective treatments for complex and widespread diseases, positioning Tune Therapeutics at the forefront of advancements in epigenetic medicine.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

GoCheck, also known as Gobiquity, Inc., specializes in mobile health applications aimed at the early detection and prevention of health disorders, particularly eye diseases. Its flagship product, GoCheck Kids, is a smartphone application designed to screen for amblyopia risk factors in children, adhering to the guidelines set by the American Association for Pediatric Ophthalmology and Strabismus. The application enables pediatric teams to conduct visual acuity assessments and photo screenings, significantly enhancing early detection efforts. GoCheck Kids is utilized by over 6,500 pediatric teams across the United States and Europe, addressing the urgent need to prevent vision impairment, a leading disabling condition in children. By leveraging the manufacturing scale of smartphones, GoCheck has made early vision screening more affordable, reducing costs by over 60%. The company, founded in 2010 and based in Aliso Viejo, California, is FDA-registered and CE certified, reflecting its commitment to quality and safety in pediatric health care.

Elligo Health Research is revolutionizing the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere.

Qvella Corporation is a Toronto-based molecular diagnostics company established in 2009 by a team of scientists and engineers. The company focuses on advancing sample preparation and detection technologies in clinical microbiology, aiming to significantly reduce the time required to obtain results. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a unique electrical lysing method known as e-lysis™, allowing for the direct and fully automated rapid detection of infectious agents from unenriched biological samples. By providing actionable results in clinically relevant time frames, Qvella seeks to improve patient outcomes and transform medical practices in the field of microbiology.

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in the development of surgical instruments designed for weight loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products is the Standard Clamp, which assists surgeons in standardizing their techniques to minimize variation, enhance efficiency, and reduce waste during procedures. Additionally, the company's disposable surgical tools complement general-use endoscopic staplers, allowing surgeons to decrease the number of cartridges used in surgeries and ultimately lowering costs. Through these innovations, Standard Bariatrics aims to improve surgical outcomes and streamline the weight loss surgery process.

Boston Immune Technologies & Therapeutics, Inc., a biopharmaceutical company, develops immune-based approaches for the treatment of cancer and infectious diseases. The company develops immunotherapy for chronic infectious diseases. The company was incorporated in 2011 and is based in Winchester, Massachusetts.

StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.

Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.

Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

NoviSci improve the health and well-being of people through principled data science.

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Qvella Corporation is a Toronto-based molecular diagnostics company established in 2009 by a team of scientists and engineers. The company focuses on advancing sample preparation and detection technologies in clinical microbiology, aiming to significantly reduce the time required to obtain results. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a unique electrical lysing method known as e-lysis™, allowing for the direct and fully automated rapid detection of infectious agents from unenriched biological samples. By providing actionable results in clinically relevant time frames, Qvella seeks to improve patient outcomes and transform medical practices in the field of microbiology.

Altis Biosystems is a biotechnology company developing research tools for the pharma and biotech industries. The company has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. Their organ on a chip product produces a layer of human or animal intestinal stem and differentiated cells, either of the small or large intestine. These cells can be used for disease modeling, precision medicine, microbiome research, and compound screening.

CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries. The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company’s lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.

AtaCor Medical, Inc. develops pacemaker system that keeps the heart and veins free from pacing leads and hardware. It offers AtaCor EV Temporary Pacing System, an implantable temporary pacing system that uses a parasternal approach for implantable, extravascular temporary pacing. The company’s AtaCor EV Temporary Pacing System advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium to restore cardiac rhythm for patients. AtaCor Medical, Inc. was incorporated in 2014 and is based in San Clemente, California.

Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.

410 Medical is a healthcare company based in Durham, North Carolina, founded in 2013. It specializes in developing a rapid infuser device designed to assist critically ill patients who require volume resuscitation. This innovative solution enables healthcare providers to quickly deliver fluids, including blood and other essential components, thereby enhancing the speed and efficiency of care for patients facing life-threatening conditions like sepsis and shock. The device allows for fast setup and minimizes provider fatigue, enabling a single healthcare provider to manage multiple patient care issues simultaneously. It is particularly beneficial in pre-hospital settings and emergency departments, where timely intervention is crucial and resources may be constrained.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company is advancing several product candidates, including GB-102, an intravitreal injection formulation currently undergoing Phase I/IIa and IIb clinical trials for wet age-related macular degeneration and Phase IIa trials for diabetic macular edema. Additionally, Graybug is developing GB-103, an annual formulation of GB-102 for diabetic retinopathy, and GB-401, a depot formulation aimed at treating primary open-angle glaucoma. The company's proprietary micro- and nanoparticle controlled release technologies are designed to deliver medications at a sustained rate, enhancing patient compliance and improving clinical outcomes.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.

Elligo Health Research is revolutionizing the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere.

Qvella Corporation is a Toronto-based molecular diagnostics company established in 2009 by a team of scientists and engineers. The company focuses on advancing sample preparation and detection technologies in clinical microbiology, aiming to significantly reduce the time required to obtain results. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a unique electrical lysing method known as e-lysis™, allowing for the direct and fully automated rapid detection of infectious agents from unenriched biological samples. By providing actionable results in clinically relevant time frames, Qvella seeks to improve patient outcomes and transform medical practices in the field of microbiology.

WalletFi offers a proprietary platform that identifies recurring charges, subscriptions, and CoF payments, and allows users and financial institutions to transfer those payments to a new card in case of re-issuance. WalletFi reduces customer churn for banks and financial institutions while also increasing customer engagement and reinforcing top-of-wallet status.

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, established in 2015. It specializes in targeted protein degradation, developing innovative small molecule therapeutics that selectively degrade proteins associated with various diseases by utilizing the body's natural protein degradation mechanisms. The company is advancing several therapeutic programs, including the IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program for hematologic malignancies and solid tumors, as well as autoimmune diseases. Through its proprietary predictive modeling platform, Kymera Therapeutics seeks to accelerate drug discovery and address previously untreatable conditions.

Qpex Biopharma develops a pipeline of agents addressing critical needs for the treatment of infectious diseases. It develops multiple antibiotic drugs intended to combat antimicrobial resistance. The company's technology is focused on targeting the treatment of infectious diseases for both inpatient and outpatient cases, deep expertise in the discovery, development and regulatory approval of anti-infective medicines, including an extensive record of working with public/private partnerships focused on new antibiotics to combat antimicrobial resistance, enabling medical businesses optimal use of products and critical needs for the treatment of infectious diseases in the inpatient and outpatient settings. It was founded in 2018 and is headquartered in San Diego, California.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, founded in 2014. The company specializes in the development of surgical instruments designed for weight loss surgeries, particularly laparoscopic sleeve gastrectomy. One of its key products is the Standard Clamp, which assists surgeons in standardizing their techniques to minimize variation, enhance efficiency, and reduce waste during procedures. Additionally, the company's disposable surgical tools complement general-use endoscopic staplers, allowing surgeons to decrease the number of cartridges used in surgeries and ultimately lowering costs. Through these innovations, Standard Bariatrics aims to improve surgical outcomes and streamline the weight loss surgery process.

Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.

Elligo Health Research is revolutionizing the clinical research industry with a novel approach to common trial challenges including patient participation and enrollment, and physician participation. They provide physicians and their patients the opportunity to participate in clinical trials using advanced health care informatics. Improved access to physicians and patients means sponsors reach trial enrollment goals faster, and new products are accelerated to market, benefiting patients everywhere.

Wildflower Health, Inc. is a San Francisco-based company that provides smartphone-based health programs designed to help healthcare payers connect with families across the United States. Its flagship offering, Due Date Plus, is a maternity program that engages women in early pregnancy and facilitates connections with healthcare providers or care managers. Additionally, Wildflower Health offers GROW, a family health program that addresses the needs of mothers and pediatric health. The company delivers tailored health milestones for families based on age and gender, along with features such as client resource integrations, on-device messaging, appointment reminders, health risk assessments, and clinical program referrals. Founded in 2012, Wildflower Health aims to enhance user engagement and improve healthcare experiences through innovative technology and design.

Founded by nurses and technology entrepreneurs, NurseGrid makes integrated, intuitive staffing and communication tools just for nurses and nursing departments. NurseGrid has two products: NurseGrid Mobile & NurseGrid Manager. NurseGrid Mobile is the easiest way for nurses and healthcare workers to manage their complex schedules, connect with colleagues, and bring more balance to their work lives. More than 300,000 nurses have downloaded NurseGrid to date and the iOS app enjoys a consistent 5 star average rating on the App Store. NurseGrid Manager allows nursing departments to simplify team communication, staffing, and schedule management, making staff and managers happier and more productive. It complements core scheduling systems such as Kronos, API, and McKesson, filling in the critical gap current technologies leave between schedule creation and timekeeping, and giving nurse leaders a cost-saving, nurse-preferred way to manage day to day staffing and scheduling needs. NurseGrid was launched in 2013.

Qvella Corporation is a Toronto-based molecular diagnostics company established in 2009 by a team of scientists and engineers. The company focuses on advancing sample preparation and detection technologies in clinical microbiology, aiming to significantly reduce the time required to obtain results. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a unique electrical lysing method known as e-lysis™, allowing for the direct and fully automated rapid detection of infectious agents from unenriched biological samples. By providing actionable results in clinically relevant time frames, Qvella seeks to improve patient outcomes and transform medical practices in the field of microbiology.

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Rodin Therapeutics, a biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros' best-in-class structural biology capabilities, and a team with deep CNS drug development and company formation experience. Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC).

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

StrideBio, Inc. creates and develops adeno-associated viral (AAV) vector technologies and therapeutics that enables gene addition, gene silencing, and gene editing modalities for rare diseases. The company develops a proprietary platform by combining structural information with accelerated evolution to create novel AAV capsids that can evade neutralizing antibodies. The company was founded in 2015 and is based in Durham, North Carolina.

Mati Inc. is a company based in Durham, North Carolina, that specializes in the production and sale of energy drinks. Founded in 2012, it offers a unique energy drink brewed from plant-based ingredients, fruit juice concentrates, and water. The flagship product, MATI, is designed to provide a healthier alternative for active and health-conscious consumers seeking to enhance their everyday performance. Mati Inc. distributes its products through various channels, including wholesalers, retail outlets, and online platforms, primarily serving customers in North Carolina and surrounding counties. As of April 2020, Mati Inc. operates as a subsidiary of NOBL Beverages.

NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

Bivarus, Inc. develops a cloud-based analytics platform for measuring continuous quality improvement (CQI) and the patient experience to hospital-based outpatient service lines, community-based clinics, and group practices through patient-centered insights. Its platform enables customers to gain insights into the drivers impacting the patient experience, buying behavior, and provider performance, as well as to improve patient care and service operations. Bivarus, Inc. was founded in 2010 and is based in Durham, North Carolina. As of January 16, 2018, Bivarus, Inc. operates as a subsidiary of Press Ganey Holdings, Inc.

HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

Boragen Inc. is a biotechnology company based in Durham, North Carolina, that specializes in designing and developing multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Founded in 2015, the company focuses on creating next-generation fungicides through its synthetic chemistry platforms, which aim to promote sustainable farming practices. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide, and BN2266, which targets mRNA processing as a crop protection fungicide. Additionally, the company is developing a dual-function nematicide-fungicide designed for root protection and endo-parasiticides that address resistance challenges. Through its innovative approach, Boragen seeks to enhance agricultural efficiency while minimizing chemical usage.

Artizan Biosciences develops small molecule drugs targeting human diseases, utilizing its IgA-SEQ technology platform to identify disease-driving bacteria within the intestinal microbiota. Founded in 2016 and headquartered in New Haven, Connecticut, the company focuses on creating new and potentially curative treatments. With a commitment to advancing pharmaceutical drug development, Artizan Biosciences aims to address unmet medical needs through innovative approaches in biotechnology.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company is advancing several product candidates, including GB-102, an intravitreal injection formulation currently undergoing Phase I/IIa and IIb clinical trials for wet age-related macular degeneration and Phase IIa trials for diabetic macular edema. Additionally, Graybug is developing GB-103, an annual formulation of GB-102 for diabetic retinopathy, and GB-401, a depot formulation aimed at treating primary open-angle glaucoma. The company's proprietary micro- and nanoparticle controlled release technologies are designed to deliver medications at a sustained rate, enhancing patient compliance and improving clinical outcomes.

Bivarus, Inc. develops a cloud-based analytics platform for measuring continuous quality improvement (CQI) and the patient experience to hospital-based outpatient service lines, community-based clinics, and group practices through patient-centered insights. Its platform enables customers to gain insights into the drivers impacting the patient experience, buying behavior, and provider performance, as well as to improve patient care and service operations. Bivarus, Inc. was founded in 2010 and is based in Durham, North Carolina. As of January 16, 2018, Bivarus, Inc. operates as a subsidiary of Press Ganey Holdings, Inc.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Qvella Corporation is a Toronto-based molecular diagnostics company established in 2009 by a team of scientists and engineers. The company focuses on advancing sample preparation and detection technologies in clinical microbiology, aiming to significantly reduce the time required to obtain results. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a unique electrical lysing method known as e-lysis™, allowing for the direct and fully automated rapid detection of infectious agents from unenriched biological samples. By providing actionable results in clinically relevant time frames, Qvella seeks to improve patient outcomes and transform medical practices in the field of microbiology.

Medfusion, Inc. operates a patient engagement portal aimed at enhancing healthcare services for providers and patients in the United States and internationally. The platform facilitates communication through various clinical, administrative, and financial services, including billing solutions such as online bill pay and payment plans, as well as secure patient messaging and prescription renewal requests. Medfusion also offers front desk solutions like appointment requests and patient registration, along with mobile applications that empower patients to access their health data. Additional services include EHR/PM integration and Practice Intelligence, which provides insights into patient communication traffic. Founded in 1996 and based in Cary, North Carolina, Medfusion originally focused on medical website development for healthcare clients, evolving to meet the specific needs of the healthcare sector.

Wildflower Health, Inc. is a San Francisco-based company that provides smartphone-based health programs designed to help healthcare payers connect with families across the United States. Its flagship offering, Due Date Plus, is a maternity program that engages women in early pregnancy and facilitates connections with healthcare providers or care managers. Additionally, Wildflower Health offers GROW, a family health program that addresses the needs of mothers and pediatric health. The company delivers tailored health milestones for families based on age and gender, along with features such as client resource integrations, on-device messaging, appointment reminders, health risk assessments, and clinical program referrals. Founded in 2012, Wildflower Health aims to enhance user engagement and improve healthcare experiences through innovative technology and design.

NuSirt Sciences, Inc. is a biotechnology company based in Nashville, Tennessee, established in 2007. It focuses on developing innovative products for the prevention and treatment of metabolic diseases related to over-nutrition, such as obesity and type 2 diabetes. The company's technology platform combines natural compounds with pharmaceutical agents to activate sirtuin pathways, aiming to reduce the dosage of metformin, a standard treatment for early-stage type 2 diabetes, which some patients find difficult to tolerate due to side effects. NuSirt's lead product, NS-0100, combines leucine with a low dose of metformin and is currently undergoing Phase 2 clinical trials to determine its efficacy. The company has filed eleven patent applications, with two patents issued, and has conducted multiple pre-clinical and clinical studies to support its patented technologies. NuSirt has also formed strategic partnerships to enhance its research and development efforts in the field.

Spyryx Biosciences is a biopharmaceutical company based in Durham, North Carolina, specializing in the development of inhaled peptide therapeutics aimed at treating obstructive lung diseases, specifically cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Founded in 2013 by Dr. Robert Tarran, the company emerged from his discovery of a novel mechanism by which the lungs regulate surface fluid. This mechanism is impaired in CF patients due to genetic mutations, leading to dehydration, mucus buildup, and subsequent lung damage. Spyryx's therapeutic approach targets this underlying dysfunction, showing promising results in preclinical studies by significantly improving survival in animal models of CF. Importantly, the treatment is designed to function independently of the specific genetic mutations responsible for CF, offering potential benefits to a broader patient population. Additionally, the company is exploring the relevance of this fluid regulation mechanism in COPD, a condition characterized by chronic bronchitis and emphysema, as part of its commitment to addressing multiple obstructive lung diseases.

Contego Medical, Inc. develops emboli protection devices that are used for the treatment of cardiovascular and endovascular diseases. It offers angioplasty balloons and stent delivery catheters, such as coronary stent systems, carotid post-dilation balloons, and renal artery stent systems with integrated embolic protection devices for enabling carotid, renal, SVG, and coronary interventions. Contego Medical, Inc. was formerly known as Contego Medical, LLC. The company was founded in 2005 and is based in Raleigh, North Carolina with an additional office in Curitiba, Brazil.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company is advancing several product candidates, including GB-102, an intravitreal injection formulation currently undergoing Phase I/IIa and IIb clinical trials for wet age-related macular degeneration and Phase IIa trials for diabetic macular edema. Additionally, Graybug is developing GB-103, an annual formulation of GB-102 for diabetic retinopathy, and GB-401, a depot formulation aimed at treating primary open-angle glaucoma. The company's proprietary micro- and nanoparticle controlled release technologies are designed to deliver medications at a sustained rate, enhancing patient compliance and improving clinical outcomes.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly affecting the heart, liver, and neurodegenerative conditions. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology, enabling the differentiation of cells into any type found in the body. This technology serves multiple purposes, including drug efficacy testing, medication toxicity screening, and facilitating personalized treatment approaches. The company's product offerings include LifeProfiles, a suite of genetic tests such as FITCODE, which provides insights into fitness-related traits; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Established in 2011 and based in Cambridge, Massachusetts, the company utilizes its expertise in lysosome-based genetic disorders to create innovative treatment options. It specifically targets conditions such as Gaucher-related neurodegeneration and Parkinson’s disease, along with other synucleinopathies. Through its research and development efforts, Lysosomal Therapeutics aims to provide new solutions for patients suffering from these challenging neurological conditions.

Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.

Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.

Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

Clinverse is a technology company solely focused on the financial management of clinical trials and associated payments in over 140 currencies. Our flagship product, ClinPay, is a secure on-line eClinical Trial Payment Network that dramatically reduces time spent on the investigator payment process with significant increases in clinical trial productivity. ClinPay links sponsors to investigators in a payment and reporting system that reduces study start-up time, makes possible timely and accurate payments, provides transparency and auditing records, and simplifies compliance.

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Established in 2011 and based in Cambridge, Massachusetts, the company utilizes its expertise in lysosome-based genetic disorders to create innovative treatment options. It specifically targets conditions such as Gaucher-related neurodegeneration and Parkinson’s disease, along with other synucleinopathies. Through its research and development efforts, Lysosomal Therapeutics aims to provide new solutions for patients suffering from these challenging neurological conditions.

Jumo Health develops age-appropriate, educational resources for patients and caregivers for use throughout their medical journey. It works with providers, manufacturers, and advocacy groups, to ensure resources are available at the moment of diagnosis, during a treatment regimen, or while participating in a clinical trial. The company was founded in 2009 and is headquartered in New York, United States.

Curoverse, Inc. develops and operates a cloud based open source platform under the name Arvados for storing, organizing, analyzing, and sharing genomic data. Curoverse, Inc. was formerly known as Clinical Future, Inc. and changed its name to Curoverse, Inc. in December 2013. The company was incorporated in 2010 and is based in Boston, Massachusetts. As of August 3, 2017, Curoverse, Inc. operates as a subsidiary of Veritas Genetics International Ltd.

Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. Founded in 2008, the company is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics is advancing several investigational therapies, including trilaciclib, an intravenous cyclin-dependent kinase (CDK) 4/6 inhibitor, currently undergoing Phase 1b/2 trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. The company is also developing lerociclib, an oral CDK4/6 inhibitor, which is in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer. Additionally, G1 Therapeutics is progressing rintodestrant, an oral selective estrogen receptor degrader, currently in Phase I/2 trials. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment in locally advanced breast cancer. G1 Therapeutics aims to improve treatment outcomes for cancer patients through its innovative therapeutic approaches.

Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

Coferon is a biotechnology company that employs bioorthogonal linker chemistry to deliver therapeutic molecules in component parts that self assembles inside target cells. The Company is based at the Long Island High Tech Incubator on the campus of Stony Brook University in Stony Brook, New York.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company's Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells. Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.

HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.

Pathfinder Therapeutics

ArtusLabs is developing and deploying Web 2.0 enabled software platforms that enable groups of scientists, and thereby individual scientists, to deliver significantly better (and more) business value to their shareholders, faster. ArtusLabs was founded by the same proven team that formed Synthematix, the award winning organization that pioneered the Enterprise Electronic Lab Notebook marketplace. This leadership and development team has extensive expertise in processing, mining and managing complex scientific data and information generated from research activities. With a wealth of experience and very close relationships with scientists around the globe, the team at ArtusLabs continues to build the best collaborative customer experience and technologies for researchers -- hands down.

SpineAlign Medical, Inc., a medical device company, develops and distributes medical devices and products to treat disorders of the spine. It offers VerteLift, a nitinol implant that is used in the treatment of vertebral compression fractures (occurs in patients suffering from osteoporosis) in the thoracic/lumbar spine. The company distributes its products in Europe. SpineAlign Medical, Inc. was formerly known as SpineWorks Medical, Inc. and changed its name to SpineAlign Medical, Inc. in May 2009. The company was founded in 2005 and is based in San Jose, California.

Clinipace Inc. is a clinical research organization that provides integrated clinical research services to pharmaceutical, biotechnology, and medical device companies in the United States and globally. Founded in 2003 and headquartered in Morrisville, North Carolina, Clinipace specializes in various therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, diabetes, and respiratory diseases. The company offers a comprehensive range of services such as biostatistics, clinical monitoring, patient recruitment, regulatory affairs, and legal representation. With additional offices in Boulder, Colorado, and international locations in Argentina, Brazil, Europe, and the Asia Pacific, Clinipace emphasizes collaboration and flexibility in its approach, distinguishing itself from traditional clinical research organizations.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileâ„¢ Technology. Viamet's disruptive Metallophileâ„¢ technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.